Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in moderate to severe hidradenitis suppurativa
NL-OMON60991Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of spesolimab in hidradenitis suppurativa (HS), sponsored by Boehringer Ingelheim. Primary endpoint: Percent change from baseline in draining tunnel count. Started Jun 2023; status: completed.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON60991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60991.